Chinese medtech regulatory system will take shape during second half of 2005
This article was originally published in Clinica
A joint high-level meeting on China's healthcare system, including its hospital and insurance systems, will be the agenda items at a China-US meeting in Beijing on July 11-12. The government and business health forum, which comes at a time when the Chinese system is in a phase of full development, will discuss ways of improving and opening up the various elements of the sector. These include the medical devices segment, which is currently valued at up to $6.5bn.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.